1文献来源
Mamounas EP,Tang G,Fisher B,et al.Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative,estrogen receptor-positive breast cancer：Results from NSABP B-1...1文献来源
Mamounas EP,Tang G,Fisher B,et al.Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative,estrogen receptor-positive breast cancer：Results from NSABP B-14 and NSABP B-20[J].J Clin Oncol,2010,28（10）：1677-1683.展开更多
1文献来源Sparano JA,Gray RJ,Makower DF, et al.Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer[J]. N Engl J Med,2018,379(2):111-121.2证据水平1b。3背景21基因复发风险评分测定(Oncotype DX,Genom...1文献来源Sparano JA,Gray RJ,Makower DF, et al.Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer[J]. N Engl J Med,2018,379(2):111-121.2证据水平1b。3背景21基因复发风险评分测定(Oncotype DX,Genomic Health)是一种通过测定特定乳腺癌基因,为激素受体阳性、腋窝淋巴结阴性的乳腺癌患者提供预后预测信息的模型,评分分值为0~100.当复发风险评分较高时(≥31,或≥26),预测患者接受辅助化疗可获益.当复发风险评分较低(0~10)时,提示患者10年内的远处复发率极低并且不大可能受辅助化疗的影响.展开更多
文摘1文献来源
Mamounas EP,Tang G,Fisher B,et al.Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative,estrogen receptor-positive breast cancer：Results from NSABP B-14 and NSABP B-20[J].J Clin Oncol,2010,28（10）：1677-1683.
文摘1文献来源Sparano JA,Gray RJ,Makower DF, et al.Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer[J]. N Engl J Med,2018,379(2):111-121.2证据水平1b。3背景21基因复发风险评分测定(Oncotype DX,Genomic Health)是一种通过测定特定乳腺癌基因,为激素受体阳性、腋窝淋巴结阴性的乳腺癌患者提供预后预测信息的模型,评分分值为0~100.当复发风险评分较高时(≥31,或≥26),预测患者接受辅助化疗可获益.当复发风险评分较低(0~10)时,提示患者10年内的远处复发率极低并且不大可能受辅助化疗的影响.
